Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Status:
Completed
Trial end date:
2009-03-31
Target enrollment:
Participant gender:
Summary
This open-label, multicenter, randomized, controlled, Phase II study is planned to answer
questions about how the drug, matuzumab (EMD 72000), works and is part of an effort aimed to
develop better treatment for advanced lung cancer by combining matuzumab, a monoclonal
antibody, with a chemotherapy treatment, called pemetrexed.